roll pro forma ci-esrx
updat model esrx deal
updat ci model acquisit express script esrx
ep estim move reflect degre conservat
part due expect ci guid conserv especi around capit
deploy potenti upsid driver includ capit deploy beyond
model model time synergi core busi perform
prior period develop result wouldnt surpris see compani
start conserv guidanc rang midpoint near
beat rais throughout year ultim deliv closer
close beyond ep guidanc look addit color
gener combin ci guid unchang po
base ep vs previous estim reflect esrx
deal reaffirm buy core busi strength upsid esrx
potenti guidanc bridg
assum smooth line ci adjust baselin high end
target would impli ep impli growth
high end ci lt ep growth target in-lin comment ci
grow averag accret esrx meanwhil take
midpoint guidanc discount back normal growth rate
would impli howev given synergi ramp pre-tax
debt paydown time see upsid est particularli
factor capit deploy think ci could achiev close low end
ep target year ahead schedul biggest variabl guidanc
capit deploy ci histor includ share repo/d seem
like floor ci doesnt includ repo rang could
midpoint rais ci repurchas stock conserv assum
expect upsid year goe
ci confid tone abil integr deal drive long-term valu
sharehold stand-alone esrx enterpris valu initi progress
ci synergi target upsid save esrx sell
season key integr risk retent level strong esrx
lower percentag book bid leav us confid outlook
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
one largest manag
organ pharmaci benefit manag
us compani also offer global
supplement benefit disabl life
esrx deal add capabl cash-flow
potenti ep upsid think ci could
achiev close low end pro forma
ep target year earli
compel aspect deal
gener much pf parent
combin
po base ep estim repres premium
five-year averag view appropri given outlook
risk po deal integr risk issu disabl life busi
compani see higher expect cost trend potenti impact futur
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
